Enspectra Health
- Company typePrivate
- Founded2012
- HeadquartersMenlo Park, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Enspectra Health firmographics
Firmographics- Name
- Enspectra Health
- Legal name
- Enspectra Health, Inc.
- Website
- https://enspectrahealth.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Enspectra Health industry classification
Industry- Product category
- Dermatology medical imaging devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Medical Imaging AI (HDAAAEAH)
Keywords
Where Enspectra Health is headquartered
LocationHeadquarters
- HQ city
- Menlo Park
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Enspectra Health business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Medical Device Sales: Sale of VIO imaging hardware system to dermatologists and healthcare providers for point-of-care skin assessments
- Software/Subscription Services: AI-powered insights and analysis capabilities bundled with the device for real-time dermatological assessments
- Service and Support: Ongoing maintenance, support, and potentially consumables associated with the imaging device
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
Enspectra Health product offering
Product offeringCore offering
Enspectra Health develops and sells the VIO™ imaging system, a handheld medical device that combines multiphoton laser scanning with reflectance confocal microscopy to deliver non-invasive, real-time high-resolution digital images of live skin cells. The device is FDA-cleared and accompanied by AI-powered analysis that enables dermatologists to perform "virtual biopsies" for evaluating conditions such as nonmelanoma skin cancers without surgical incisions.
Product overview
Enspectra Health offers a single unified product—the VIO™ imaging system—which combines multiphoton laser scanning with reflectance confocal microscopy in a handheld device. The VIO system enables clinicians to perform virtual biopsies, generating high-resolution digital images of live cells without incisions and providing AI-powered insights for dermatological assessments. The technology has received FDA clearance for clinical use in evaluating skin conditions including nonmelanoma skin cancers.
Differentiator
Problem solved
Functional benefit
Products and services
- VIO™ Imaging System A handheld skin imaging system that combines multiphoton laser scanning with reflectance confocal microscopy to deliver actionable cellular information noninvasively in real time. It enables dermatologists to perform "virtual biopsies" for evaluating nonmelanoma skin cancers and broader skin conditions without surgical incisions, and is paired with AI-powered analysis to support point-of-care decision-making. Intended for dermatologists, dermatology practices, hospitals, and healthcare systems.
Quantifiable outcome
- Validated in VISTA Trial published in JAMA Dermatology showing high accuracy for noninvasive identification of key skin features
- +2 more outcomes
Companies that use Enspectra Health
Customer profileSegments3 records
Ideal customer profiles3 records
Enspectra Health technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature4 records
Enspectra Health partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- UCSFcoreUniversity of California San Francisco partnership for research and clinical development of the imaging technology
- StanfordcoreStanford University partnership for clinical research and technology development
- Mass General BrighamcoreMajor healthcare system partnership for clinical validation and research collaboration
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Enspectra Health competitors and assessment
Company assessmentDirect peers
- Caliber Imaging & Diagnostics (VivaScope): Caliber I&D manufactures the VivaScope, a reflectance confocal microscopy system for non-invasive skin imaging. It is the closest direct competitor to Enspectra's VIO system, as both aim to provide non-invasive cellular-level visualization of skin at the point of care.
- Michelson Diagnostics (VivoSight): Michelson Diagnostics offers the VivoSight optical coherence tomography + confocal system for dermatology imaging. It competes directly with Enspectra in non-invasive skin imaging for lesion evaluation and shares the same enterprise dermatology customer base.
- MetaOptima Technology (DermEngine): MetaOptima's DermEngine is an AI-powered dermatoscopy and tele-dermatology platform used by dermatologists for lesion tracking and AI-assisted assessment. It directly overlaps with Enspectra's AI-powered skin health assessment value proposition and target buyer.
Broad incumbents
- Canfield Scientific: Canfield Scientific is the leading dermatology imaging vendor (VECTRA, IntelliStudio, VISIA) used by dermatologists and plastic surgeons for total body photography and lesion documentation. It is a broad incumbent in dermatology imaging workflows that Enspectra must integrate alongside or displace.
- FotoFinder Systems: FotoFinder provides AI-assisted total body dermatoscopy and mole mapping systems widely used by dermatology practices globally. As a broad incumbent in dermatology imaging with AI, it represents the established workflow that Enspectra's point-of-care cellular imaging would complement or compete with.
- Verily Life Sciences (Alphabet): Verily, an Alphabet health-tech company, has invested in dermatology AI and clinical research tools through partnerships and internal programs. As a broad incumbent with deep capital and data resources, it represents a well-capitalized competitive threat in AI dermatology.
- STRATA Skin Sciences (formerly Mela Sciences): STRATA Skin Sciences markets dermatology imaging and diagnostic systems to dermatology practices. As a public dermatology imaging incumbent, it represents an established commercial channel and a potential acquirer or competitor for Enspectra's VIO technology.
- 3Gen (DermLite): DermLite is a market-leading manufacturer of handheld dermatoscopes used in nearly every dermatology practice. It is a broad incumbent in the point-of-care skin imaging workflow that Enspectra is targeting with its VIO handheld form factor.
Emerging players
- Skin Analytics: Skin Analytics is an emerging AI dermatology company (DERM) with regulatory clearances for autonomous skin cancer triage in the UK and EU. It competes in the same AI dermatology triage market as Enspectra but is currently focused on teledermatology and primary care pathways.
- SkinVision: SkinVision offers a smartphone-based AI app for skin lesion risk assessment with regulatory clearances in Europe. It is an emerging player in AI dermatology triage and overlaps with Enspectra's thesis that non-invasive AI tools can reduce unnecessary biopsies.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Enspectra Health social profiles
Digital presenceEnspectra Health compliance and trust
Trust signalCompliance1 record
Enspectra Health financial estimates
Financial estimateRevenue estimate
Valuation estimate
Enspectra Health leadership team
Management profileNumber of profiles
Profiles2 records
Enspectra Health funding detail
Funding detailFunding overview
Funding rounds6 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Enspectra Health M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Enspectra Health
What does Enspectra Health do?
Enspectra Health develops and sells the VIO™ imaging system, a handheld medical device that combines multiphoton laser scanning with reflectance confocal microscopy to deliver non-invasive, real-time high-resolution digital images of live skin cells. The device is FDA-cleared and accompanied by AI-powered analysis that enables dermatologists to perform "virtual biopsies" for evaluating conditions such as nonmelanoma skin cancers without surgical incisions.
Is Enspectra Health a public or private company?
Enspectra Health is a private company. It is classified as venture growth investor backed and is currently operating.
When was Enspectra Health founded?
Enspectra Health was founded in 2012. It employs 1 to 10 people.
Where is Enspectra Health based?
Enspectra Health is headquartered in Menlo Park, United States, in the North America region.
How does Enspectra Health make money?
Three revenue lines are on record. Medical Device Sales are the primary driver. The others are software/Subscription Services and service and Support.
Who are Enspectra Health's main competitors?
Direct peers on record are Caliber Imaging & Diagnostics (VivaScope), Michelson Diagnostics (VivoSight) and MetaOptima Technology (DermEngine). Broad incumbents are Canfield Scientific, FotoFinder Systems, Verily Life Sciences (Alphabet), STRATA Skin Sciences (formerly Mela Sciences) and 3Gen (DermLite). Emerging players are Skin Analytics and SkinVision.
Does Enspectra Health have an API?
No public API is recorded for Enspectra Health.
What industry is Enspectra Health in?
Enspectra Health's product category is Dermatology medical imaging devices. Its primary akta.pro industry code is HDAAAEAH, Medical Imaging AI. Its NAICS code is 334510 and its SIC code is 3841.